| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:SARS-CoV-2 Mpro-IN-9
CAS:2754370-99-3
Purity:99.00% Package:1mg;2mg;5mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:SARS-CoV-2 Mpro-IN-9
CAS:2754370-99-3
Purity:99.78% Package:1mg/RMB 1980;2mg/RMB 2970;5mg/RMB 4920
|
SARS-CoV-2 Mpro-IN-9 manufacturers
- SARS-CoV-2 Mpro-IN-9
-
- $293.00 / 1mg
-
2025-11-10
- CAS:2754370-99-3
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
|
| | SARS-CoV-2 Mpro-IN-9 Basic information |
| | SARS-CoV-2 Mpro-IN-9 Chemical Properties |
| Boiling point | 638.184±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.413±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 6.057±0.20(predicted) |
| | SARS-CoV-2 Mpro-IN-9 Usage And Synthesis |
| Uses | SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC50=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC50>50 μM)[1]. | | References | [1] Zhang K, et al. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro). Eur J Med Chem. 2023 Sep 5;257:115487. DOI:10.1016/j.ejmech.2023.115563 |
| | SARS-CoV-2 Mpro-IN-9 Preparation Products And Raw materials |
|